Radiation & immunotherapy combo tested for rare skin cancer
NCT ID NCT04261855
Summary
This study is testing whether combining an immunotherapy drug (avelumab) with a form of targeted radiation therapy can better control advanced Merkel cell carcinoma, a rare and aggressive skin cancer. It aims to see if this combination is safe and can help stop the cancer from growing for longer. The trial is for adults with metastatic disease who have not yet received other treatments for their advanced cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MERKEL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Gosford Hospital
Gosford, New South Wales, 2250, Australia
-
Lake Macquarie Private Hospital
Gateshead, New South Wales, 2290, Australia
-
Mid North Coast Cancer Institute - Coffs Harbour Health Campus
Coffs Harbour, New South Wales, 2450, Australia
-
Peter MacCallum Cancer Centre
Melbourne, Victoria, 3000, Australia
-
Princess Alexandra Hospital
Brisbane, Queensland, 4102, Australia
-
Royal Adelaide Hospital
Adelaide, South Australia, 5000, Australia
-
Royal Brisbane and Women's Hospital
Brisbane, Queensland, 4029, Australia
-
Royal North Shore Hospital
Sydney, New South Wales, 2065, Australia
-
Sir Charles Gaidner Hospital
Perth, Western Australia, 6009, Australia
-
Wyong Hospital
Hamlyn Terrace, New South Wales, 2259, Australia
Conditions
Explore the condition pages connected to this study.